From the Journals

Most patients with lichen sclerosus receive appropriate treatment


 

FROM THE INTERNATIONAL JOURNAL OF WOMEN’S DERMATOLOGY

Most clinicians are appropriately prescribing high-potency steroids for vulvar lichen sclerosus, but the recent analysis of a large commercial insurance database suggests that the condition may be underdiagnosed.

Steroids prescribed to lichen sclerosus patients by provider type

The claims-based prevalence of 0.05% found in the study is lower than previously reported, and only 16% of the diagnoses were in women aged 18-44 years, Laura E. Melnick, MD, and associates wrote after identifying 10,004 females aged 0-65 years with lichen sclerosus in the IBM MarketScan Commercial Claims and Encounters Databases from 2015 to 2017. The majority (79%) of those diagnosed were aged 45-65 years (average, 50.8 years).

In pediatric patients (up to age 17 years), the low prevalence (0.01%) “may be attributable to several factors including relative rarity, as well as variability in pediatric clinicians’ familiarity with [lichen sclerosus] and in patients’ clinical symptoms,” said Dr. Melnick and associates in the department of dermatology at New York University.

Just over half of all diagnoses (52.4%) were made by ob.gyns., with dermatologists next at 14.5%, followed by family physicians (6.5%), nurse practitioners (2.5%), and internists (0.4%), they reported in the International Journal of Women’s Dermatology.

Treatment for lichen sclerosus, in the form of high-potency topical corticosteroids, was mostly appropriate. Ob.gyns. prescribed class 1/2 steroids to 83% of their patients, tops among all clinicians. Dermatologists were just over 80%, and the other clinician categories were all over 70%, the investigators said.

“Understanding the current management of [lichen sclerosus] is important given that un- or undertreated disease can significantly impact patients’ quality of life, lead to increased lower urinary tract symptoms and irreversible architectural changes, and predispose women to squamous cell carcinoma,” they wrote.

SOURCE: Melnick LE et al. Int J Womens Dermatol. 2020. doi: 10.1016/j.ijwd.2020.05.001.

Recommended Reading

Most dermatologic drugs safe for breastfeeding mothers
MDedge ObGyn
Consider different etiologies in patients with vaginal pruritus
MDedge ObGyn
Many common dermatologic drugs can be safely used during pregnancy
MDedge ObGyn
Consider cutaneous endometriosis in women with umbilical lesions
MDedge ObGyn
Common drug with lots of surprising side effects
MDedge ObGyn
Antifungal drug appears safe for pregnancy
MDedge ObGyn
Skin manifestations are emerging in the coronavirus pandemic
MDedge ObGyn
Itchy, vesicular rash
MDedge ObGyn
Case reports illustrate heterogeneity of skin manifestations in COVID patients
MDedge ObGyn
Dermatologic changes with COVID-19: What we know and don’t know
MDedge ObGyn